Form 8-K - Current report:
SEC Accession No. 0001193125-23-251917
Filing Date
2023-10-06
Accepted
2023-10-06 06:06:59
Documents
19
Period of Report
2023-10-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d534693d8k.htm   iXBRL 8-K 37178
2 EX-1.1 d534693dex11.htm EX-1.1 261674
3 EX-4.1 d534693dex41.htm EX-4.1 65246
4 EX-5.1 d534693dex51.htm EX-5.1 12312
5 EX-99.1 d534693dex991.htm EX-99.1 9983
9 GRAPHIC g534693g1005133831379.jpg GRAPHIC 3106
10 GRAPHIC g534693g1006025058484.jpg GRAPHIC 3252
11 GRAPHIC g534693g1006025058803.jpg GRAPHIC 1414
  Complete submission text file 0001193125-23-251917.txt   616411

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA alxo-20231004.xsd EX-101.SCH 2862
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE alxo-20231004_lab.xml EX-101.LAB 17235
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alxo-20231004_pre.xml EX-101.PRE 10820
13 EXTRACTED XBRL INSTANCE DOCUMENT d534693d8k_htm.xml XML 3290
Mailing Address 323 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 323 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-466-7125
ALX ONCOLOGY HOLDINGS INC (Filer) CIK: 0001810182 (see all company filings)

EIN.: 850642577 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39386 | Film No.: 231312540
SIC: 2834 Pharmaceutical Preparations